Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of ceftobiprole diffusion in bone and joint in patients with bone and joint infection undergoing hip or knee replacement
2017-001327-45Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2017
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceftobiprole medocaril in Bone and osteoarticular infections (BJI), osteomyelitis (OM) and bacterial disease, sponsored by Hospices Civils de Lyon. Primary endpoint: Ceftobiprole concentrations in blood, bone, and synovial fluid. Started Sep 2017; status: active.
02
Drugs
ceftobiprole medocaril
03
Conditions
Bone and osteoarticular infections (BJI)osteomyelitis (OM)bacterial disease
Beyond the preview
Go deeper on 2017-001327-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001327-45.